Gilead Stock News

The FDA has placed a clinical hold on Gilead Sciences Inc's (NASDAQ: GILD) injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and pre-exposure prophylax

(RTTNews) - Gilead Sciences Inc. (GILD) said that the U.S. Food and Drug Administration has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis. The FDA''s clinical hold is due to emerging concerns about the compatibility of vials

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on the use of injectable lenacapavir in borosilicate vials in all ongoing clinical studies for HIV treatment and HIV pre-exposure prophylaxis (PrEP). The FDAs clinical hold is due to emerging concerns about the compatibility of vials made of borosilicate glass with lenacapavir solution, which could potentially lead to the formati

Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) today announced the closing of Gileads option exercises to three progra

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GileadIR--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare Conference and Q&A Breakout on Monday, January 10 beginning at 11:15 a.m. Eastern Time The live webcast can be accessed at the companys investors page at investors.gilead.com. The replay will be available for at least 30 days following the presentation. About Gilead Sciences Gilead Sciences, Inc. is a bi

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GileadIR--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference: J.P. Morgan Healthcare

The European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Gilead Sciences Inc''s (NASDAQ: GILD ) Veklury (remdesivir) to include adults who do not require supplemental oxygen and are at an increased risk of progressing to severe COVID-19. This decision follows the favorable recommendation of the Committee for Medicinal Products for Human Use (CHMP). Results from a Phase 3 Full story available on Benzinga.com

PALM BEACH, Fla. , Dec. 21, 2021 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - Breast cancer is cancer that develops in the breast tissue. Breast cancer signs include the formation of a lump in the breast and red patches on the skin. Obesity, lack of physical activity, excessive radiation exposure, and alcohol use are all risk factors for breast cancer. Breast cancer is more prevalent in developed countries than it is in developing countries. Post diagnosis, cancer therapy requires different procedures depending upon the form and severity of cancer. The cancer care market is increasing at a substantial pace due to the rise in the occurrence of cancer cases, growing knowledge among people about different stages, and availability of treatment of cancer. Breast cancer treatment relies on different factors, such as breast cancer origin, tumor size, and breast cancer phase, and cancer grade. Operations, radiation therapy, chemotherapy, hormone therapy, targeted therapy, and bone-led therapy are some of the most popular approaches used in the management of breast cancer.

The European Commission (EC) has approved a variation to the Conditional Marketing Authorization for Gilead Sciences Inc's (NASDAQ: GILD) Veklury (remdesivir) to include adults who do not require

5 Dividend Growth Stocks With 4%+ Yields

TOKYO, Dec 20, 2021 - (JCN Newswire) - Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib (generic

Financial Avengers Inc. cut its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,158 shares of the biopharmaceutical companys stock after selling 229 shares during the period. Financial Avengers Inc.s holdings []

Related Stocks: JPM , SCHW , CERN , GILD , BKR , CTSH , XOM , SLB , MDT , KDP , KSS , OGN , SNN , TFC , CM , INTC , BDX , KMTUY ,

Pinnacle Wealth Planning Services Inc. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 4.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,464 shares of the biopharmaceutical companys stock after purchasing an additional 286 shares during the quarter. []

Atwood & Palmer Inc. lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.5% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 217,942 shares of the biopharmaceutical companys stock after buying an additional 3,300 shares during the quarter. Atwood & Palmer []